Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb;480(2):825-839.
doi: 10.1007/s11010-024-05063-4. Epub 2024 Jul 10.

The E2F family: a ray of dawn in cardiomyopathy

Jinwen Wei  1 , Can Gao  1 , Changxu Lu  1 , Lijie Wang  2 , Dan Dong  3 , Mingli Sun  4
Affiliations
Review

The E2F family: a ray of dawn in cardiomyopathy

Jinwen Wei et al. Mol Cell Biochem. 2025 Feb.

Abstract

Cardiomyopathies are a group of heterogeneous diseases, characterized by abnormal structure and function of the myocardium. For many years, it has been a hot topic because of its high morbidity and mortality as well as its complicated pathogenesis. The E2Fs, a group of transcription factors found extensively in eukaryotes, play a crucial role in governing cell proliferation, differentiation, and apoptosis, meanwhile their deregulated activity can also cause a variety of diseases. Based on accumulating evidence, E2Fs play important roles in cardiomyopathies. In this review, we describe the structural and functional characteristics of the E2F family and its role in cardiomyocyte processes, with a focus on how E2Fs are associated with the onset and development of cardiomyopathies. Moreover, we discuss the great potential of E2Fs as biomarkers and therapeutic targets, aiming to provide a reference for future research.

Keywords: Biomarkers; Cardiomyopathies; E2F family; Therapeutic targets; Transcription factors.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors have no relevant financial or non-financial interests to disclose.

Similar articles

See all similar articles

References

    1. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D et al (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113(14):1807–1816. https://doi.org/10.1161/CIRCULATIONAHA.106.174287 - DOI - PubMed
    1. Mckenna WJ, Maron BJ, Thiene G (2017) Classification, epidemiology, and global burden of cardiomyopathies. Circ Res 121(7):722–730. https://doi.org/10.1161/CIRCRESAHA.117.309711 - DOI - PubMed
    1. Sun H, Chen D, Xin W, Ren L, Li Q, Han X (2023) Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy. Front Pharmacol 14:1146651. https://doi.org/10.3389/fphar.2023.1146651 - DOI - PubMed - PMC
    1. Boulestreau R, Gosse P, Doublet J, Cremer A (2023) Malignant hypertensive cardiomyopathy: definition matters. J Am Coll Cardiol 81(8):e57–e58. https://doi.org/10.1016/j.jacc.2022.11.058 - DOI - PubMed
    1. Baik SK, Fouad TR, Lee SS (2007) Cirrhotic cardiomyopathy. Orphanet J Rare Dis 2:15. https://doi.org/10.1186/1750-1172-2-15 - DOI - PubMed - PMC

Substances

LinkOut - more resources